Trial Profile
A Multicenter, Phase III, Open-Label, Randomized Study in Previously Untreated Patients With Advanced Indolent Non-Hodgkin's Lymphoma Evaluating the Benefit of GA101 (RO5072759) Plus Chemotherapy Compared With Rituximab Plus Chemotherapy Followed by GA101 or Rituximab Maintenance Therapy in Responders
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 16 Feb 2024
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms GALLIUM
- Sponsors Chugai; Nippon Shinyaku; Roche
- 14 Feb 2024 The trial has been completed in Hungary,according to European Clinical Trials Database record.
- 14 Dec 2023 Results of analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma, published in the Journal of Clinical Oncology
- 12 Dec 2023 Results(n=221)investigating the value of the ctDNA as a treatment agnostic stratification tool, presented at the 65th American Society of Hematology Annual Meeting and Exposition.